PDCD1 and neoplasm: The binding of PD-L1 on tumor cells to PD-1 on tumor-infiltrating T cells (TILs) promotes the activation of Src homology region 2 domain-containing phosphatases (SHP2), which inhibits the T-cell receptor (TCR) signaling pathway and inhibits the function of T cells.